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INTRODUCTION
Granulocytic sarcoma (GS) is a localized tumor composed
of immature myeloid cells in extramedullary sites. It usually
presents concomitantly with or after the onset of acute myel-
ogenous leukemia (AML), blastic phase of chronic myeloge-
nous leukemia or myelodysplastic syndrome (1-3). On rare
occasions, GS may present as nonleukemic GS. By definition,
nonleukemic GS occurs without present overt leukemia, and
in the absence of any past history of AML, myelodysplasia,
or myeloproliferative disorders (2-4). Nonleukemic GS may
involve any part of the body, and the most common sites of
involvement are skin, subcutaneous tissue, lymph nodes, cen-
tral nervous system, gastrointestinal tract, mediastinum, bone,
breast, ovary and uterus (2, 3, 5). Although nonleukemic GS
may be found in any location, primary occurrence in the bile
duct is extremely rare. In this report, we describe an extremely
rare case of a nonleukemic GS of the bile duct, which was
initially misdiagnosed as a bile duct carcinoma arising in the
hilum of the liver (so-called Klatskin tumor). 
CASE REPORT
A 44-yr-old man was hospitalized because of jaundice. Phy-
sical examination revealed normal findings except jaundice.
His past medical history was unremarkable. The complete
blood count showed hemoglobin of 15 g/dL, white blood cell
count of 8,200/ L (differential 79% segmented neutrophils,
15% lymphocytes, 5% monocytes, and 1% eosinophils), and
platelet count of 248,000/ L. Liver function test showed ele-
vation of total bilirubin, direct bilirubin, and alkaline phos-
phatase (15.3 mg/dL, 9.4 mg/dL and 298 IU/L, respectively).
Computed tomography of the abdomen revealed thickening
of common bile duct wall, luminal narrowing at common
hepatic duct level and mild, diffuse dilatation of intrahepatic
duct (Fig. 1). Magnetic resonance cholangiography showed
dilatation of both intrahepatic duct and right posterior duct
(Fig. 2). Based on these findings, a common hepatic duct can-
cer (Klatskin tumor) was thought to be the cause of the obstruc-
tive jaundice. He underwent a right lobectomy of the liver. 
Histological examination of the tumor showed diffuse thick-
ening of the common bile duct wall with encroachment of
the lumen and obliteration of the mucosal folds by the dense
cellular infiltrate. The great majority of the cells in the infil-
trate consisted of myeloid precursors with large round to oval
cells with slightly eosinophilic cytoplasm and round to oval
vesicular nuclei, admixed with a minor population of more
mature myeloid forms including eosinophils (Fig. 3). Immu-
nohistochemical stains showed tumor cells positive for leuko-
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Nonleukemic Granulocytic Sarcoma in the Bile Duct
: A Case Report
Granulocytic sarcoma (GS) is an extramedullary tumor composed of immature mye-
loid cells, typically occurring during the course of acute myelogenous leukemia. Non-
leukemic GS, that is, GS with no evidence of overt leukemia and no previous history
of leukemia, is very rare, and even more unusual is nonleukemic GS of the bile duct.
We report a case of nonleukemic GS of the bile duct. The patient was initially mis-
diagnosed as a bile duct carcinoma arising in the hilum of the liver (so-called Klatskin
tumor), and received a right lobectomy of the liver. Histological examination of the
tumor yielded the diagnosis of GS, and the bone marrow biopsy did not show any
evidence of leukemia. Considering the risk of subsequent development of overt
leukemia, the patient was treated with two cycles of combination chemotherapy as
used in the cases of acute myelogenous leukemia. To date, he has remained free
of disease 15 months after treatment. 
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Accepted : 4 August 2005cyte common antigen (CD 45) and myeloperoxidase (Fig. 4),
and negative for CD 3, 4, 5, 8, 10, 21, 23, 56 and terminal
deoxynucleotidyl transferase. Bone marrow aspirate and biopsy
showed neither significant abnormalities nor evidence of
myelodysplasia or leukemic infiltration. In consequence of
these findings, the tumor was diagnosed as nonleukemic GS.
Considering the risk of subsequent development of overt
leukemia (3), the patient received antileukemic induction
chemotherapy consisting of cytarabine 200 mg/m2/day (days
1-5) and daunorubicin 45 mg/m2/day (days 1-3), and a course
of consolidation with high dose cytarabine (cytarabine 6 g/
m2/day, days 1, 3, 5) subsequently. To date, he has remained
free of disease for 15 months.
DISCUSSION
Nonleukemic GS is very rare disease. Although nonleukemic
GS may involve any part of the body, nonleukemic GS of
the bile duct is extremely rare.
To the best of our knowledge, there have been only 1 case
report of nonleukemic GS of the bile duct in the medical
literatures. Matsueda et al. (6) reported a patient who present
with obstructive jaundice and underwent endoscopic retro-
grade biliary drainage. He developed acute AML within 1
month. 
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Fig. 2. Magnetic resonance cholangiography showing dilatation
of both intrahepatic duct and right posterior duct. 
Fig. 3. The great majority of the cells in the infiltrate consists of mye-
loid precursors with large round to oval cells with slightly eosinophilic
cytoplasm and round to oval vesicular nuclei, admixed with a minor
population of more mature myeloid forms including eosinophils
(hematoxilin-eosin, ×400). 
Fig. 1. Abdominal computed tomography demonstrating thickening of common bile duct wall, luminal narrowing at common hepatic duct
level (A), and mild, diffuse dilatation of intrahepatic duct (B). 
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A frequent problem reported with nonleukemic GS is ini-
tial misdiagnosis. Correct initial diagnosis of nonleukemic
GS is very important because misdiagnosis could lead to inap-
propriate treatment and hence, to the risk of missing a chance
for cure. However, due to its rarity, nonleukemic GS is fre-
quently misdiagnosed as other common malignancies, as
was the case with our patient being initially misdiagnosed
as a bile duct carcinoma. Even after the histologic examina-
tion, GS may be misdiagnosed as other malignancies, most
often as lymphoma (2, 3). Because considerable cases of GS
do not show morphologic evidence of granulocytic differen-
tiation, could exhibit features mimicking lymphoma and
may co-express myeloid and lymphoid markers, histologic
diagnosis of GS can be difficult if it is not suspected (1, 7). In
one case series, 75% of the cases with nonleukemic GS were
initially misdiagnosed, 50% as lymphoma, and 25% as non-
hematopoietic neoplasm (2). In another case series, 35 (47%)
of 74 patients with nonleukemic GS were initially misdiag-
nosed (5). Among them, 31 patients were mistaken for lym-
phoproliferative disorders. The correct diagnoses were usually
made when the lesion recurred or after overt leukemia devel-
oped thereafter (2, 5). Consequently, treatment was inappro-
priate or delayed under the initial misdiagnosis in these cases.
Thus, for correct initial diagnosis and adequate therapy, it is
important to suspect the possibility of nonleukemic GS and
to apply appropriate immunohistochemical staining for dif-
ferential diagnosis. 
Nonleukemic GS represents therapeutic dilemma as well
as a diagnostic one because the optimal therapy for nonleu-
kemic GS has not been determined. Several previous reports
showed that more than 80% of patients with nonleukemic
GS who were treated by surgical excision or local radiation
therapy eventually developed overt systemic leukemia with-
in a matter of months (1, 3, 8, 9), which suggests that local
treatments such as surgical excision or radiation therapy would
not be sufficient for the treatment of nonleukemic GS. For
this, the importance of systemic chemotherapy as used for
AML early in the course of the disease was advocated by sev-
eral retrospective studies (2, 5, 10). Eshghabadi et al. (2) found
that in the 19 patients who received surgical or radiation ther-
apy for nonleukemic GS eventually developed AML. In con-
trast, only 5 (42%) of 11 patients treated with systemic che-
motherapy developed AML. A Canadian study (10) provides
further evidence for the importance of systemic therapy early
in the course of nonleukemic GS. In this retrospective review
of 90 nonleukemic GS cases, patients treated with systemic
chemotherapy had a decreased probability of developing AML
and experienced longer overall survival. In all, 59 (66%) of
the 90 patients developed AML at a median 9 months after
the diagnosis of nonleukemic GS and the median overall
survival was 22 months. A total of 49 (54%) of 90 patients
received chemotherapy and were less likely to develop AML
as compared with those who did not receive chemotherapy
(41% vs. 71%, p=0.001). In addition, leukemia occurred
significantly later in those patients who received systemic
chemotherapy. The median time from diagnosis of nonleuke-
mic GS to leukemia was 36 months in patients treated with
chemotherapy compared with 6 months in untreated patients.
Most importantly, the overall survival was longer in the pa-
tients who received chemotherapy than in the patients who
did not (more than 50% alive after a median follow up of 25
months compared with a median survival of 13 months in
those who did not receive chemotherapy). Of note is that mul-
tivariate analysis revealed that neither radiation nor surgery
alone had any effect on survival. Yamauchi and Yasuda (5)
reported 74 cases of nonleukemic GS. These patients were
divided into 3 groups by therapeutic regimens; Group I in-
cluded 12 patients who received only biopsy or surgical resec-
tion of the tumor, Group II was 20 patients who received
local radiation, and Group III consisted of 42 patients who
received systemic chemotherapy. The nonleukemic period
after the diagnosis of GS was significantly longer in Group
III than in the other groups (median, 12 months in Group
III vs. 3 and 6 months in Group I and II, respectively). Accord-
ing to the findings of the above studies, it appeared that pati-
ents with nonleukemic GS should receive AML type systemic
chemotherapy at the time of diagnosis, and surgery and/or
radiation therapy alone would be insufficient treatment of
nonleukemic GS. In the present case, considering the risk of
subsequent development of overt leukemia, we treated the
patient with two cycles of AML type combination chemother-
apy and he has remained free of disease 15 months after treat-
ment. A few patients with nonleukemic GS also underwent
Fig. 4. Immunohistochemical stain for myeloperoxidase (MPO)
reveals positive granular cytoplasmic staining of most of the myeloid
cells except for the most immature precursors, and the epithelial
cells of the bile ducts (×400). 748 H.W. Kim, S.-J. Choi, J.-H. Lee, et al.
allogeneic or autologous bone marrow transplantation (10).
However, the efficacy of allogeneic or autologous bone mar-
row transplantation in the therapy of nonleukemic GS has
not been defined. 
In conclusion, nonleukemic GS is frequently misdiagnosed
as other more common malignancies because of its rarity and
clinico-pathological features mimicking other malignancies.
With a high index of suspicion, the application of immuno-
histochemical techniques enables the differential diagnosis
from aggressive lymphoma that represents the commonest
misdiagnosis. Considering the poor outcome after local treat-
ment for nonleukemic GS, the patients with nonleukemic GS
should be treated with intensive AML type systemic chemo-
therapy early in the course of the disease. 
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